BMY

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.79
Percentage change -1.62	%

Peers: PFE JNJ MRK LLY ABBV GILD AMGN AZN NVS

| Held by: VTI VOO SCHD SPY IVV VTV XLV VYM JEPI VHT

Scroll to Statements

Index	S&P 500	P/E	17.98	EPS (ttm)	2.66	Insider Own	0.08%	Shs Outstand	2.04B	Perf Week	-2.70%
Market Cap	97.48B	Forward P/E	7.94	EPS next Y	6.03	Insider Trans	0.31%	Shs Float	2.03B	Perf Month	-19.10%
Income	5.42B	PEG	0.25	EPS next Q	1.68	Inst Own	79.85%	Short Float	1.48%	Perf Quarter	-19.73%
Sales	47.64B	P/S	2.05	EPS this Y	494.82%	Inst Trans	2.46%	Short Ratio	2.27	Perf Half Y	-9.21%
Book/sh	8.54	P/B	5.61	EPS next Y	-11.86%	ROA	5.66%	Short Interest	30.03M	Perf Year	-2.22%
Cash/sh	5.79	P/C	8.27	EPS next 5Y	72.54%	ROE	31.99%	52W Range	39.35 - 63.33	Perf YTD	-15.31%
Dividend Est.	2.48 (5.19%)	P/FCF	7.45	EPS past 5Y	-	ROI	8.35%	52W High	-24.36%	Beta	0.42
Dividend TTM	2.44 (5.09%)	Quick Ratio	1.17	Sales past 5Y	15.21%	Gross Margin	59.16%	52W Low	21.73%	ATR (14)	1.96
Dividend Ex-Date	Apr 04, 2025	Current Ratio	1.28	EPS Y/Y TTM	186.41%	Oper. Margin	22.93%	RSI (14)	26.55	Volatility	3.52% 4.05%
Employees	34100	Debt/Eq	2.95	Sales Y/Y TTM	4.62%	Profit Margin	11.38%	Recom	2.64	Target Price	56.79
Option/Short	Yes / Yes	LT Debt/Eq	2.73	EPS Q/Q	120.45%	Payout	-	Rel Volume	1.23	Prev Close	48.69
Sales Surprise	4.73%	EPS Surprise	20.43%	Sales Q/Q	-5.60%	Earnings	Apr 24 BMO	Avg Volume	13.24M	Price	47.90
SMA20	-9.64%	SMA50	-15.28%	SMA200	-11.07%	Trades		Volume	16,290,683	Change	-1.62%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-25	Initiated	Piper Sandler	Overweight
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$55
Dec-16-24	Upgrade	Jefferies	Hold → Buy	$70
Dec-10-24	Resumed	BofA Securities	Neutral	$63
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-13-24	Upgrade	Daiwa Securities	Neutral → Outperform
Nov-12-24	Upgrade	Leerink Partners	Market Perform → Outperform	$73
Oct-25-24	Downgrade	Citigroup	Buy → Neutral	$75 → $55
Oct-17-24	Initiated	Bernstein	Mkt Perform	$56
Jul-29-24	Downgrade	Barclays	Overweight → Equal Weight	$41
Mar-11-24	Downgrade	Societe Generale	Buy → Hold
Feb-06-24	Downgrade	Redburn Atlantic	Buy → Neutral	$77 → $54
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $60
Nov-15-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$68 → $55
Nov-09-23	Initiated	Deutsche Bank	Hold	$55
Nov-02-23	Downgrade	Daiwa Securities	Outperform → Neutral	$68 → $54
Oct-27-23	Upgrade	HSBC Securities	Reduce → Hold	$55 → $53
Oct-27-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-27-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$60
Oct-20-23	Resumed	UBS	Neutral	$70 → $60

Show Previous Ratings

Today 09:22AM	Immunocore Holdings: A Name On My Watch List (Seeking Alpha)
Apr-26-25 06:05PM	4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off (Motley Fool)
06:45AM	What Moved Markets This Week (Seeking Alpha)
01:53AM	Dividend Champion, Contender, And Challenger Highlights: Week Of April 27 (Seeking Alpha)
Apr-25-25 10:27AM	5 Positives From Bristol-Myers Squibb's Q1 2025 Results (Seeking Alpha)
09:25AM	Loading…
09:25AM	Company News for Apr 25, 2025 (Zacks)
09:15AM	Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? (Seeking Alpha)
09:00AM	Bristol-Myers: Undervalued, Delivering Increased 2025 Guidance (Seeking Alpha)
08:37AM	Bristol-Myers Squibb Company (BMY): A Growing Dividend Stock with Low PE Ratio (Insider Monkey)
Apr-24-25 04:45PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
04:12PM	Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat (Investor's Business Daily)
12:11PM	Netflix's new high, Bristol Myers outlook, Texas Instruments pops (Yahoo Finance Video)
12:01PM	Bristol-Myers Squibb Company (BMY) Q1 2025 Earnings Call Transcript (Seeking Alpha)
11:56AM	Bristol-Myers Squibb Is A Good Pick (Seeking Alpha)
11:54AM	BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook (Zacks)
11:35AM	Loading…
11:35AM	Jobless Claims Increased in Line With Expectations (Zacks)
11:22AM	Bristol-Myers Q1 Earnings Review: A Decidedly Mixed Bag - Rating Downgrade (Seeking Alpha)
10:35AM	Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings Estimates (Investor's Business Daily)
10:32AM	A Busy Morning: Jobless Claims, Durable Goods & Q1 Earnings (Zacks)
10:14AM	Stocks Climb as Fed-Cut Hopes Sink Treasury Yields: Markets Wrap (Bloomberg)
09:30AM	Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics (Zacks)
08:10AM	Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
07:47AM	Bristol-Myers Squibb (NYSE:BMY) Reports Upbeat Q1, Full-Year Outlook Slightly Exceeds Expectations (StockStory)
06:59AM	Bristol Myers Squibb Reports First Quarter Financial Results for 2025 (Business Wire)
Apr-23-25 12:37PM	Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More (Zacks)
10:20AM	Is Bristol-Myers Squibb Company (BMY) the Best Stock That Will Always Grow? (Insider Monkey)
09:25AM	The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi (Zacks)
08:01AM	Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect (StockStory)
Apr-22-25 06:05PM	Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025 (Seeking Alpha)
05:25PM	Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test (Investor's Business Daily)
05:25PM	Loading…
05:25PM	Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test (Investor's Business Daily)
04:15PM	Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia (Business Wire)
10:00AM	NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:40AM	Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term (Zacks)
09:06AM	Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast? (Zacks)
08:26AM	Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY) (TipRanks)
07:09AM	Iovance Biotherapeutics: Only For The Brave (Seeking Alpha)
06:21AM	Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession (Seeking Alpha)
Apr-19-25 07:00AM	Bristol Myers says FDA updates Camzyos label to simplify treatment (TipRanks)
Apr-18-25 09:15AM	Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Apr-17-25 08:21PM	U.S. Food and Drug Administration Updates CAMZYOS (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications (Business Wire)
01:06PM	Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings? (Zacks)
10:00AM	Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
06:20AM	Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar? (Zacks)
Apr-16-25 05:51PM	Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity (Seeking Alpha)
05:45PM	Bristol Myers Squibb (BMY) Stock Moves -1.35%: What You Should Know (Zacks)
05:24PM	Is Bristol-Myers Squibb Company (BMY) The Dirt Cheap Stock To Invest In Now? (Insider Monkey)
04:27PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
01:07PM	Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News (Zacks)
01:05PM	Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? (Zacks)
Apr-15-25 01:38PM	Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy for Long Term Growth? (Insider Monkey)
08:17AM	BMY Down on Heart Drug Camzyos Failure in Late-Stage Study (Zacks)
08:00AM	Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis (PR Newswire)
07:35AM	Bristol-Myers Squibb Company (BMY): Among the Best Value Dividend Stocks to Buy According to Billionaires? (Insider Monkey)
Apr-14-25 06:15PM	Bristol Myers Slumps On Heart Drug Failure Taking Cytokinetics With It (Investor's Business Daily)
04:15PM	Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial (Business Wire)
09:00AM	Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Apr-12-25 10:26AM	Schrodinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade) (Seeking Alpha)
07:50AM	What Moved Markets This Week (Seeking Alpha)
Apr-11-25 04:09PM	Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market (Investor's Business Daily)
03:58PM	Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires? (Insider Monkey)
03:49PM	U.S. Food and Drug Administration Approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma (Business Wire)
08:15AM	Warning For SCHD Investors: Tariffs Are A Major Risk (Seeking Alpha)
Apr-10-25 12:58PM	S&P, Dow Jones Pharma Names Rattled Again On Trump's Tariffs Whiplash (Investor's Business Daily) -6.10%
05:00AM	The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb (Zacks)
Apr-09-25 05:45PM	Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today (Zacks)
03:37PM	Bristol-Myers Squibb Company (BMY): Among the High Growth Dividend Paying Stocks to Invest in (Insider Monkey)
01:45PM	Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More (Zacks)
01:44PM	BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo (Zacks)
05:40AM	Trump Says Pharmaceutical Tariffs Coming Very Shortly (Bloomberg)
Apr-08-25 03:36PM	U.S. Food and Drug Administration Approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1 (Business Wire)
Apr-05-25 09:01AM	SCHD: Buy The Dip And Call It A Day (Seeking Alpha)
08:14AM	Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout (Seeking Alpha)
Apr-04-25 08:07PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
Apr-03-25 10:50AM	The Zacks Analyst Blog Highlights Exxon Mobil, Bristol-Myers Squibb, Chubb and Hamilton Beach Brands (Zacks)
10:30AM	Pharma Stocks Aren't in the Clear, Despite Tariff ExemptionHeard on the Street (The Wall Street Journal)
Apr-02-25 04:26PM	Top Research Reports for Exxon Mobil, Bristol-Myers Squibb & Chubb (Zacks)
03:00PM	Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More (Zacks)
05:40AM	Is Bristol Myers Squibb's High-Yielding Dividend Safe? (Motley Fool)
Apr-01-25 03:00PM	CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo (Zacks)
12:10PM	Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:11AM	Impax Ellevate Global Women's Leadership Fund Q4 2024 Commentary (Seeking Alpha)
09:52AM	Is Bristol-Myers Squibb (BMY) One of the Best Healthcare Stocks to Buy According to Billionaires? (Insider Monkey)
09:00AM	Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:00AM	Beat the S&P 500 With This Cash-Gushing Dividend Stock (Motley Fool)
Mar-31-25 03:03PM	Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (Seeking Alpha)
02:10PM	Bristol-Myers Squibb Company (BMY): Among the Best High Yield Stocks to Buy in April for Dividend Capture (Insider Monkey)
11:23AM	March Madness: SCHD Dividend Bracketology (Part 1) (Seeking Alpha)
Mar-30-25 08:00AM	Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025) (Seeking Alpha)
05:00AM	Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors (Seeking Alpha)
03:25AM	abrdn Healthcare Opportunities Fund Q4 2024 Commentary (Seeking Alpha)
Mar-29-25 09:38AM	Jim Cramer on Bristol-Myers Squibb. Co (NYSE:BMY): They Should Have Known Better (Insider Monkey)
06:47AM	What Moved Markets This Week (Seeking Alpha)
01:55AM	Dividend Champion, Contender, And Challenger Highlights: Week Of March 30 (Seeking Alpha)
Mar-28-25 10:31PM	Why Bristol-Myers Squibb Co. (BMY) Went Up On Friday? (Insider Monkey)
09:44AM	AbbVie Vs. Sanofi: Which Is The Better Investment Right Now (Seeking Alpha)
08:53AM	Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1... (Business Wire)
08:00AM	Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications (Business Wire)
Mar-27-25 03:00PM	FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors (Zacks)
11:00AM	Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form (Yahoo Finance)

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Apr 01 '25	Option Exercise	0.00	3,306	0	15,489	Apr 03 05:15 PM
Plenge Robert M	EVP, Chief Research Officer	Mar 10 '25	Option Exercise	0.00	11,255	0	20,148	Mar 12 09:39 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Mar 10 '25	Option Exercise	0.00	23,150	0	26,937	Mar 12 09:37 PM
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Mar 10 '25	Option Exercise	0.00	20,423	0	22,339	Mar 12 09:35 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	Mar 10 '25	Option Exercise	0.00	16,684	0	20,017	Mar 12 09:34 PM
Poole Ahn Amanda	EVP, Chief People Officer	Mar 10 '25	Option Exercise	0.00	7,164	0	8,546	Mar 12 09:32 PM
LEUNG SANDRA	EVP, General Counsel	Mar 10 '25	Option Exercise	0.00	48,718	0	386,496	Mar 12 09:32 PM
Hoch Lynelle	President, Cell Therapy Org.	Mar 10 '25	Option Exercise	0.00	7,446	0	7,920	Mar 12 09:31 PM
Holzer Phil M	SVP and Controller	Mar 10 '25	Option Exercise	0.00	7,140	0	17,870	Mar 12 09:31 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Mar 10 '25	Option Exercise	0.00	44,098	0	99,040	Mar 12 09:30 PM
Gallman Cari	EVP, Corporate Affairs	Mar 10 '25	Option Exercise	0.00	7,588	0	11,626	Mar 12 09:29 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10 '25	Option Exercise	0.00	69,517	0	252,608	Mar 12 09:28 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Mar 10 '25	Option Exercise	0.00	60,034	0	152,898	Mar 12 09:27 PM
Hickey Benjamin	President, RayzeBio Org.	Mar 01 '25	Option Exercise	0.00	3,286	0	10,419	Mar 04 05:44 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Feb 20 '25	Buy	55.05	2,000	110,096	104,626	Feb 21 07:09 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Feb 14 '25	Buy	54.84	1,823	100,000	63,932	Feb 19 07:19 PM
Hickey Benjamin	President, RayzeBio Org.	Feb 01 '25	Option Exercise	0.00	10,078	0	10,858	Feb 04 07:05 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Feb 01 '25	Option Exercise	0.00	2,543	0	7,829	Feb 04 07:04 PM
Holzer Phil M	SVP and Controller	Nov 04 '24	Sale	55.62	700	38,930	11,760	Nov 05 05:53 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Nov 01 '24	Option Exercise	0.00	2,964	0	104,169	Nov 05 05:42 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Nov 01 '24	Buy	54.67	1,830	100,055	62,109	Nov 05 05:41 PM
Holzer Phil M	Officer	Nov 04 '24	Proposed Sale	55.62	700	38,930		Nov 04 11:20 AM
Gallman Cari	EVP, Corporate Affairs	Oct 02 '24	Option Exercise	0.00	4,558	0	6,667	Oct 03 06:33 PM
Gallman Cari	EVP, Corporate Affairs	Aug 01 '24	Option Exercise	0.00	1,061	0	2,493	Aug 05 06:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Bristol-Myers Squibb Co

Upgrade your FINVIZ experience